# Quest Diagnostics Q3 2026 Earnings Call

> Quest raises 2026 revenue guidance after 10% jump to $3.1B but warns of $120M PAMA cuts for 2027.
- Title: Quest Diagnostics Q3 2026 Earnings Call · BigGo Finance
- Summary: Quest raises 2026 revenue guidance after 10% jump to $3.1B but warns of $120M PAMA cuts for 2027. Quest Diagnostics reported Q3 2026 revenue of $3.1 billion…
- Keywords: quest diagnostics, pama, results act, revenue, revenue guidance, q3 2026, earnings call, reimbursement cuts, 2027, 120 million, 10 percent, 3.1 billion
- Source: BigGo Finance — https://finance.biggo.com/news/US_DGX_2026-10-22
- Author: BigGo Finance
- Published: 2026-10-22T14:54:17+00:00
- Read time: 1 min
- Topics: quest diagnostics, pama, results act, revenue, revenue guidance, q3 2026, earnings call, reimbursement cuts, 2027, 120 million, 10 percent, 3.1 billion
## Q3 2026 Results
Quest Diagnostics reported third-quarter 2026 revenues of $3.1 billion, up 10% year-over-year, and adjusted earnings per share of $3.00, a 15.4% increase.
## Guidance Raised
The company raised full-year 2026 revenue guidance to $12.065 billion to $12.105 billion, reflecting 9.3% to 9.7% growth.
## PAMA Impact
Quest estimates a ~1% revenue hit (~$120 million) for 2027 due to flawed PAMA data collection process.
## PAMA Data Concerns
CEO Jim Davis noted independent labs accounted for 76.5% of reported volume to CMS, while hospital outreach was less than 10%.
## RESULTS Act Push
Quest is pushing for the bipartisan RESULTS Act, with a CBO score expected mid-November 2026.
## Cybersecurity Incident
Quest disclosed unauthorized access to a test ordering system but said operations were not materially disrupted.
## Apple Health Partnership
Quest announced a partnership with Apple Health to allow lab ordering directly from the app.
## Consumer Health Growth
Consumer health revenue grew over 30% for the full year, highlighted by new Apple Health integration.
## Advanced Diagnostics
Advanced diagnostics revenue grew double-digit, including cardiometabolic, hormone, and Alzheimer’s disease testing.
## PAMA Code Cuts
775 codes face maximum 15% reduction, and 1,200 of 1,550 codes will be cut under PAMA.
## 2027 Impact Estimate
Quest estimates cumulative PAMA impact for 2027 through 2029 will be less than 1.3% of total revenues.
## 2027 Guidance
Quest expects 2027 revenue guidance with Q4 results early next year and an Investor Day on March 25, 2027.
## Key takeaway

Quest Diagnostics reported Q3 2026 revenue of $3.1 billion, up 10% year-over-year, and raised full-year guidance but warned of potential $120 million in 2027 reimbursement cuts from flawed PAMA data collection.